J Korean Soc Clin Pharmacol Ther. 2006 Dec;14(2):106-115. Korean.
Published online Feb 20, 2020.
Copyright © 2006 Korean Society for Clinical Pharmacology and Therapeutics
Original Article

Pharmacokinetic and Pharmacodynamic Comparative Study of Amlodipine Adipate and Amlodipine Besylate

Ji-Young Jeon, Jung-Ryul Kim, Jae-Yong Chung, Dal-Seok Oh, Joo-Youn Cho, Kyung-Sang Yu, In-Jin Jang, and Sang-Goo Shin
    • Department of Pharmacology and Clinical Pharmacology Unit, Seoul National University, College of Medicine and Hospital, Seoul, Korea.

It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).

Abstract

Background

Amlodipine is a dihydropyridine calcium antagonist used for the treatment of hypertension and angina. Amlodipine adipate is a newly developed salt formulation of amlodipine. The purpose of this study was to compare the pharmacokinetic and pharmacodynamic characteristics of amlodipine adipate with those of conventional amlodipine besylate in healthy subjects.

Methods

The study was conducted as a single blinded, block dose randomized, two-way crossover design. Twenty-four subjects were enrolled, twelve subjects each for the 5 mg dose group and the 10 mg dose group. Subjects were administered single oral dose of amlodipine adipate and amlodipine besylate, in a randomized sequence, with two weeks washout period between the two treatments. Serial blood samples were collected till 120 hours after drug administration. Plasma concentrations of amlodipine were analyzed by liquid chromatography tandem mass spectrometry. Individual pharmacokinetic parameters were calculated by noncompartmental methods and the pharmacokinetic parameters were analyzed by analysis of variance. Ambulatory blood pressure and computerized impedance cardiography were measured till 24 hours after drug administration. The pharmacodynamic parameters were analyzed by repeated-measures analysis of variance.

Results

In the 5 mg dose group, the ratios of AUClast and Cmax of amlodipine adipate to amlodipine besylate were 0.93 and 0.89, respectively. In the 10 mg dose group, the ratios of AUClast and Cmax of amlodipine adipate to amlodipine besylate were 1.01 and 1.09, respectively. Regarding pharmacodynamic results, there were no significant differences in systolic blood pressure, diastolic blood pressure, pulse rate, or in change of total peripheral resistance between amlodipine adipate and amlodipine besylate at doses of both 5 mg and 10 mg.

Conclusions

We concluded that amlodipine adipate and amlodipine besylate showed similar pharmacokinetic and pharmacodynamic characteristics.

Keywords
Amlodipine adipate; Amlodipine besylate; Pharmacokinetics; Pharmacodynamics


Metrics
Share
PERMALINK